AstraZeneca PLC (LON:AZN) target price raised to 5,050.00GBX, reported today by Jefferies International
- Updated: September 18, 2016
Only yesterday AstraZeneca PLC (LON:AZN) traded 2.02% higher at 5,017.00GBX. AstraZeneca PLC’s 50-day moving average is 5,017.86GBX and its 200-day average is 4,330.50GBX. With the last close up 17.65% from the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the date range. 4,505,466 shares of AZN traded, up from ann average trading volume of 2,849,440.
In a statement issued on 8/4/2016 Jefferies International raised the target price of AstraZeneca PLC (LON:AZN) from 4,800GBX to 5,050GBX reporting a possible upsideof 0.01%.
On Tuesday August 2 2016, Exane BNP Paribas released a statement on AstraZeneca PLC(LON:AZN) upped the target price from 0.00GBX to 5,300.00GBX that suggested an upside of 0.05%.
See Graph Below:
A total of 29 firms have released a research note on the stock. Four analysts rate the company a strong buy, 14 firms rate the stock a buy, 13 analyts rate the company a hold, two brokerages rate the stock to underperform, and finally one analystrate the company as sell with a one year target price of 61.96GBX
With a market cap of 0.0 GBX, AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a price-earnings ratio of 29.
General Company Details For AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, and among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.